Life sciences group SkinBioTherapeutics PLC (LON:SBTX) remains on track to kick off the human study of its SkinBiotix technology in September after receiving provisional ethics approval from regulators.
Full approval will be granted on completion of procedural amendments to the study paperwork which are underway.
READ: SBTX to collaborate as industry partner in 'probiotic' skin research grant
“Ethics approval is a prerequisite for human clinical trials and therefore required before our human study can commence,” said chief executive Catherin O’Neill.
“The procedural amendments we need to make to the paperwork are straightforward and consequently we remain on track to commence the human study in September.”
The study will test whether the positive impact of SkinBiotix on the skin’s barrier function, which has been shown in laboratory studies, is replicated with human volunteers.
Around 120 volunteers with self-assessed ‘dry skin’ will take part in the six-week trial.